Hemodynamic and Renal Effects of Atrial Natriuretic Peptide in Congestive Heart Failure Michael A. Fifer, MD, Cesar R. Molina, MD, Antonio C. Quiroz, MD, Thomas D. Giles, MD, Howard C. Herrmann, MD, Ivan R. De Scheerder, MD, Denis L. Clement, MD, PhD, Spencer Kubo, MD, Robert J. Cody, MD, Jay N. Cohn, MD, and Michael B. Fowler, MD
The hemodynamic and renal effects of anaritide (human atrial natriuretic peptide 102-126), a synthetic analog of atrial natriuretic peptide, were evaluated in 35 patients with chronic New York Heart Association class II to IV heart failure. There were 32 men and 3 women, aged 33 to 75 (mean f standard error of the mean 56 f 2) years. In the first phase of the study, right-sided heart catheterization was performed, and anaritide was administered as l-hour infusions. The rate of the infusion varied among patients from 0.03 to 0.3 j&g/min. In response to anatftide, there were decreases in mean systemic arterial (S4 f 2 to 87 f 2 mm Hg), right atrial (10 f 1 to 8 f 1 mm Hg), mean pulmonary arterial (33 f 2 to 26 f 2 mm Hg) and pulmonary artery wedge (22 f 2 to 15 f 2 mm Hg) pressures (all p
The hemodynamic and renal effects of anaritide (human atrial natriuretic peptide 102-126), a synthetic analog of atrial natriuretic peptide, were evaluated in 35 patients with chronic New York Heart Association class II to IV heart failure. There were 32 men and 3 women, aged 33 to 75 (mean f standard error of the mean 56 f 2) years. In the first phase of the study, right-sided heart catheterization was performed, and anaritide was administered as l-hour infusions. The rate of the infusion varied among patients from 0.03 to 0.3 j&g/min. In response to anatftide, there were decreases in mean systemic arterial (S4 f 2 to 87 f 2 mm Hg), right atrial (10 f 1 to 8 f 1 mm Hg), mean pulmonary arterial (33 f 2 to 26 f 2 mm Hg) and pulmonary artery wedge (22 f 2 to 15 f 2 mm Hg) pressures (all p
